Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14548912 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL24319959 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL13343274 | 1.00 | EPHX1 (0.50) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL23784041 | 0.98 | EPHX1 (0.46) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL18455001 | 0.98 | EPHX1 (0.46) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL12257891 | 0.98 | EPHX1 (0.46) | EPHX1LMNAKISS1RSIGMAR1HTR2A | |
| SCHEMBL17900058 | 0.90 | — | — | |
| SCHEMBL13213381 | 0.90 | — | — | |
| SCHEMBL11651306 | 0.90 | — | — | |
| SCHEMBL20094137 | 0.87 | EPHX1 (0.39) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206325-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-10675358-B2 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | BOLT BIOTHERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675358-B2 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | EPHX1 422/4885LMNA 4842/4885KISS1R 3589/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | EPHX1 4180/4885LMNA 566/4885KISS1R 2381/4885 |
| US-20190076547-A1 | ANTIBODY ADJUVANT CONJUGATES | FCGR1A, FCGR3B, FCGR2A | EPHX1 417/4885LMNA 4851/4885KISS1R 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.